摘要
目的 比较艾迪注射液加化疗与单纯化疗对晚期非小细胞肺癌的疗效、毒副反应及免疫功能的影响。方法 将 98例晚期非小细胞肺癌患者随机分为两组。治疗组 :化疗同时加用艾迪注射液 60～ 80ml溶于生理盐水 40 0ml中静脉滴注 ,每天 1次 ,连用 8～ 10天。对照组 :单用化疗。化疗方案为NP方案 ,即去甲长春花碱 (NVB)联合顺铂 (DDP)。 3～ 4周为一周期 ,患者至少治疗两周期。结果 治疗组有效率为5 3 .1%,对照组为 44 .9%,差异无显著性 (P >0 .0 5 )。治疗组病变进展率、血液毒副反应、胃肠道反应、治疗前后免疫功能改变均明显低于对照组 ,差异均有显著性 (P <0 .0 5 )。治疗组生活质量KPS评分高于对照组 ,差异有显著性 (P <0 .0 5 )。结论 艾迪注射液配合化疗治疗晚期非小细胞肺癌 ,可降低化疗对患者免疫功能的影响及毒副反应 。
Objective To compare the therapeutic effect, adverse reaction and effect on immunity of chemotherapy combined Aidi injection (AI) with those of chemotherapy alone in the treatment of advanced non small cell lung cancer (NSCLC). Methods Ninety eight cases of advanced NSCLC were randomly divided into two groups, trial group and control group. In the trial group, NP plus AI (60 80 ml) were given intravenously by dissolving in 400 ml of normal saline per day for 8 10 days, while in the control group, only NP chemotherapy was given. Navelbine (25 mg/m 2, d1, 8) and cisplastin (40 mg/m 2, d1 3) were chosen in the chemotherapy. Each patient received at least two cycles of treatment. Results The effective rate in the trial group and the control group was 53.1% and 44.9% respectively, without significant difference between the two groups ( P >0.05). But the rate of progression, adverse reactions in bone marrow and digestive tract, and change of immunity in the trial group were all lower than those in the control group ( P <0.05), and the improvement in Karnofsky score in the trial group was higher than that in the control group ( P <0.05). Conclusion Chemotherapy of NP combined with AI shows benefit in the treatment of advanced NSCLC. AI could decrease the influence on immunity and adverse reaction of chemotherapy, and improve the quality of life in patients with NSCLC.
出处
《中国肺癌杂志》
CAS
2004年第3期247-249,共3页
Chinese Journal of Lung Cancer
关键词
非小细胞肺癌
化疗
艾迪注射液
毒副反应
免疫功能
Non-small cell lung cancer Chemotherapy Aidi Injection Toxic and adverse reaction Immune function
